Corporate Information

"Preparing for change before change beckons. Harnessing the power of innovative research. Providing high-quality medicines for a healthier world. This is our world at Wockhardt."

Wockhardt has created a strong and growing presence in pharmaceutical formulations, biopharmaceuticals, nutrition products, vaccines and active pharmaceutical ingredients (API's) sold in over 90 countries across the globe. All of Wockhardt's manufacturing facilities have the approval of major regulatory bodies, including the US FDA and the UK MHRA.

To see our Wockhardt Corporate Profile, click here or visit our corporate website at www.wockhardt.com

Management Team

"An experienced leadership team of industry professionals committed to serving the US healthcare marketplace with high-quality products and innovative treatment solutions and education."

Kurt Orlofski President, Wockhardt USA, Inc. and Morton Grove Pharmaceuticals, Inc.
Jerry Jabbour VP & General Counsel
Mike Craney VP Sales & Marketing, Generics
Dominick DiPaolo VP Quality & Compliance
Steve Kondracki VP Supply Chain
Chinnaiah Sivakumar AVP Operations & Restructuring
Prakash Chainani AVP Finance & IT
Gopal Venkatesan AVP Business Development
Surendra Chirra Sr. Director Tech Services & NPD
Andrew Watson Director Brand Marketing
Ralph Hodash Director Regulatory Affairs

USA History

"Wockhardt has a strong track record of acquisition management, forming strategic alliances and developing a world-class organization and culture."

Wockhardt Limited created its US subsidiary Wockhardt USA in early 2004 with a modest portfolio of three FDA-approved generic products.  Since inception, Wockhardt’s business has steadily increased in the US.  Only four years later, Wockhardt USA now has a product line of 24 oral solid and injectable products.

Chicago-based Morton Grove Pharmaceuticals was acquired by Wockhardt Limited in October 2007 in order to expand Wockhardt’s product line in the US.  Since 1995, Morton Grove has been a leading manufacturer and marketer of oral liquid and topical pharmaceuticals.  The company's core products are manufactured in its 125,000 square foot, state-of-the-art facility.

To see USA highlights, click here.

Wockhardt acquires Morton Grove in the US

  2008, Wockhardt USA, All Rights Reserved
Legal Disclaimer    |    Terms of Use    |    Privacy Policy